QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$6.51
+3.2%
$5.92
$5.26
$11.38
$260.79M0.66582,632 shs514,506 shs
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$13.19
+0.7%
$14.27
$8.66
$19.14
$1.82B1.551.63 million shs957,456 shs
AtriCure, Inc. stock logo
ATRC
AtriCure
$23.10
+0.9%
$31.60
$22.48
$59.61
$1.12B1.38675,861 shs1.11 million shs
NuVasive, Inc. stock logo
NUVA
NuVasive
$39.75
$39.64
$35.17
$49.53
$2.08B1.071.16 million shsN/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-0.94%-4.54%+17.50%+6.23%-30.58%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-1.50%-6.43%+0.08%-12.96%-16.03%
AtriCure, Inc. stock logo
ATRC
AtriCure
-4.94%-13.72%-28.75%-32.47%-46.05%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.00%0.00%0.00%0.00%-6.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
4.7446 of 5 stars
3.54.00.04.23.63.31.3
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
4.1395 of 5 stars
3.51.00.03.32.75.00.6
AtriCure, Inc. stock logo
ATRC
AtriCure
1.6369 of 5 stars
3.51.00.00.01.92.50.6
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
3.00
Buy$14.25118.89% Upside
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
3.00
Buy$23.6379.11% Upside
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$55.57140.57% Upside
NuVasive, Inc. stock logo
NUVA
NuVasive
2.50
Moderate Buy$51.3329.14% Upside

Current Analyst Ratings

Latest NUVA, ATRC, ANGO, and ATEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00
4/5/2024
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$12.00
3/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $23.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
3/20/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $22.00
3/4/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
2/28/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $58.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $42.00
2/16/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $46.00
2/9/2024
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$26.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
$338.75M0.77$1.12 per share5.81$9.64 per share0.68
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$482.26M3.77N/AN/A$0.57 per share23.14
AtriCure, Inc. stock logo
ATRC
AtriCure
$399.24M2.80N/AN/A$9.84 per share2.35
NuVasive, Inc. stock logo
NUVA
NuVasive
$1.23B1.70$4.96 per share8.01$17.02 per share2.34

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
-$52.44M-$4.84N/AN/AN/A-60.21%-3.48%-2.68%7/10/2024 (Estimated)
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$186.64M-$1.55N/AN/AN/A-38.70%N/A-27.93%5/2/2024 (Estimated)
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.66N/AN/AN/A-7.62%-7.55%-5.83%5/1/2024 (Confirmed)
NuVasive, Inc. stock logo
NUVA
NuVasive
$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/A

Latest NUVA, ATRC, ANGO, and ATEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.20N/A+$0.20N/AN/AN/A  
2/27/2024Q4 2023
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$0.28-$0.37-$0.09-$0.37$131.90 million$138.00 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/AN/AN/AN/AN/A
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
N/AN/AN/AN/AN/A
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
NuVasive, Inc. stock logo
NUVA
NuVasive
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
N/A
2.29
1.62
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
6.54
2.86
1.99
AtriCure, Inc. stock logo
ATRC
AtriCure
0.15
3.57
2.66
NuVasive, Inc. stock logo
NUVA
NuVasive
0.50
1.25
0.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
89.43%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
66.35%
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
NuVasive, Inc. stock logo
NUVA
NuVasive
N/A

Insider Ownership

CompanyInsider Ownership
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
5.10%
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
29.12%
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
NuVasive, Inc. stock logo
NUVA
NuVasive
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
81540.06 million38.01 millionOptionable
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
839137.98 million97.80 millionOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20048.38 million46.83 millionOptionable
NuVasive, Inc. stock logo
NUVA
NuVasive
3,00052.45 million52.17 millionOptionable

NUVA, ATRC, ANGO, and ATEC Headlines

SourceHeadline
This Week in Chancery Court: Poison Pill Ruling, NuVasiveThis Week in Chancery Court: Poison Pill Ruling, NuVasive
news.bloomberglaw.com - April 15 at 8:58 AM
Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032Bone Grafting Screw Market Segmentation Analysis, Share, Trends, Size, Key Players, and Forecast 2024 to 2032
taiwannews.com.tw - April 12 at 7:59 AM
10 robots used in spine surgery10 robots used in spine surgery
beckersspine.com - April 10 at 6:27 PM
Global Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market PlayersGlobal Polymeric Biomaterials Market 10 Year Forecast Report 2024-2034, with Company Profiles of the Top 10+ Major Market Players
finance.yahoo.com - April 9 at 10:20 AM
Accelus adds 2 leadersAccelus adds 2 leaders
beckersspine.com - April 3 at 3:20 PM
$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028$14.3 Bn Spinal Implants Markets: Devices, Biologics, Stimulators, VCF, Spinal Decompression, Fusion, Non-Fusion - Global Forecast to 2028
finance.yahoo.com - April 3 at 10:19 AM
Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%Spine Pain Market Expected to Reach US$12.47 Billion by 2033 with CAGR of 5%
fmiblog.com - April 2 at 2:16 PM
Globus Medical director sells $550K in stockGlobus Medical director sells $550K in stock
beckersspine.com - March 20 at 4:48 PM
Orthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGROrthopedic Navigation Systems Market Will Increase USD 8.9 Billion By 2033 with 12.7% CAGR
pharmiweb.com - March 14 at 9:11 AM
Wrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.usWrist Replacement Orthopedic Devices Market on Course to Achieve USD 618.9 Million by 2033 | Market.us
pharmiweb.com - March 13 at 10:23 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets™
prnewswire.co.uk - March 13 at 10:23 PM
UK reinstates modified MAGEC X system for scoliosis treatmentsUK reinstates modified MAGEC X system for scoliosis treatments
msn.com - March 13 at 5:22 PM
Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033Pediatric Orthopedic Implant Market Forecast Highlights 7.4% Growth Rate, Reaching USD 7.1 Billion by 2033
pharmiweb.com - March 12 at 4:16 PM
Orthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust GrowthOrthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust Growth
finance.yahoo.com - March 12 at 4:16 PM
Minimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarketsMinimally Invasive Surgery Market Worth $74.6 billion | MarketsandMarkets
finanznachrichten.de - March 12 at 9:26 AM
NuVasive and Zimmer Biomet welcomed by MedAccred programNuVasive and Zimmer Biomet welcomed by MedAccred program
medicalplasticsnews.com - March 6 at 4:00 PM
J. Kurt Jacobus, Ph.D. Joins CurvaFix Board of DirectorsJ. Kurt Jacobus, Ph.D. Joins CurvaFix Board of Directors
finance.yahoo.com - March 5 at 2:31 PM
Crushed Great Ormond Street hospital patients left in limbo after treatment axedCrushed Great Ormond Street hospital patients 'left in limbo' after treatment axed
express.co.uk - February 22 at 9:18 AM
Great Ormond Street patient cant get MAGEC spine operationGreat Ormond Street patient can't get MAGEC spine operation
newsshopper.co.uk - February 22 at 12:47 AM
Q4 2023 Globus Medical Inc Earnings CallQ4 2023 Globus Medical Inc Earnings Call
uk.finance.yahoo.com - February 21 at 2:46 PM
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration RisksGlobus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
markets.businessinsider.com - February 21 at 2:46 PM
Layoffs beget layoffs: Why 2024 could be the year of cut costs'Layoffs beget layoffs': Why 2024 could be the year of cut costs
beckersasc.com - February 19 at 8:11 PM
Orthopedic Implants Market is anticipated to reach US$ 68.71 Billion by 2028, at CAGR 5.51% GrowthOrthopedic Implants Market is anticipated to reach US$ 68.71 Billion by 2028, at CAGR 5.51% Growth
medgadget.com - February 15 at 9:38 AM
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference CallGlobus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
markets.businessinsider.com - February 13 at 9:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AngioDynamics logo

AngioDynamics

NASDAQ:ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
Alphatec logo

Alphatec

NASDAQ:ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
NuVasive logo

NuVasive

NASDAQ:NUVA
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.